Non alcoholic steatohepatitis - pipeline review, h1 2014


Published on

This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.

Published in: Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Non alcoholic steatohepatitis - pipeline review, h1 2014

  1. 1. Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014 This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline table Of Contents table Of Contents 2 list Of Tables 7 list Of Figures 8 introduction 9 global Markets Direct Report Coverage 9 non-alcoholic Steatohepatitis Overview 10 therapeutics Development 11 pipeline Products For Non-alcoholic Steatohepatitis Overview 11 pipeline Products For Non-alcoholic Steatohepatitis Comparative Analysis 12 non-alcoholic Steatohepatitis Therapeutics Under Development By Companies 13 non-alcoholic Steatohepatitis Therapeutics Under Investigation By Universities/institutes 16 non-alcoholic Steatohepatitis Pipeline Products Glance 17 clinical Stage Products 17 early Stage Products 18 non-alcoholic Steatohepatitis Products Under Development By Companies 19 non-alcoholic Steatohepatitis Products Under Investigation By Universities/institutes 21 non-alcoholic Steatohepatitis Companies Involved In Therapeutics Development 22 isis Pharmaceuticals, Inc. 22 daiichi Sankyo Company, Limited 23 novo Nordisk A/s 24 mochida Pharmaceutical Co., Ltd. 25 kissei Pharmaceutical Co., Ltd. 26 genfit Sa 27 orchid Chemicals & Pharmaceuticals Ltd 28 la Jolla Pharmaceutical Company 29 prometic Life Sciences Inc. 30 immuron Limited 31 phenex Pharmaceuticals Ag 32 wellstat Therapeutics Corporation 33 zafgen Inc. 34 conatus Pharmaceuticals Inc. 35 intercept Pharmaceuticals, Inc. 36 Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014
  2. 2. obio Pharmaceutical Holdings Limited 37 tobira Therapeutics, Inc. 38 jenken Biosciences, Inc 39 kyorin Pharmaceutical Co., Ltd. 40 nasvax Ltd. 41 stelic Institute & Co. 42 galmed International Ltd. 43 connexios Life Sciences Pvt. Ltd. 44 kadmon Pharmaceuticals, Llc 45 non-alcoholic Steatohepatitis Therapeutics Assessment 46 assessment By Monotherapy Products 46 assessment By Target 47 assessment By Mechanism Of Action 50 assessment By Route Of Administration 53 assessment By Molecule Type 55 drug Profiles 57 gft-505 - Drug Profile 57 product Description 57 mechanism Of Action 57 r&d Progress 57 kd-025 - Drug Profile 59 product Description 59 mechanism Of Action 59 r&d Progress 59 obeticholic Acid - Drug Profile 60 product Description 60 mechanism Of Action 60 r&d Progress 60 liraglutide - Drug Profile 63 product Description 63 mechanism Of Action 63 r&d Progress 63 aramchol - Drug Profile 65 product Description 65 mechanism Of Action 65 r&d Progress 65 emricasan - Drug Profile 66 product Description 66 mechanism Of Action 66 r&d Progress 66 atorvastatin Calcium - Drug Profile 69 product Description 69 mechanism Of Action 69 r&d Progress 69 anti-cd3 Oral Immunotherapy - Drug Profile 70 product Description 70 mechanism Of Action 70 r&d Progress 70 imm-124e - Drug Profile 72 product Description 72 mechanism Of Action 72 r&d Progress 72 px-102 - Drug Profile 74 product Description 74 mechanism Of Action 74 r&d Progress 74 icosapent Ethyl - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 blx-1002 - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 tranilast - Drug Profile 78 product Description 78 mechanism Of Action 78 r&d Progress 78 Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014
  3. 3. px-104 - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 tipelukast - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 gr-md-02 - Drug Profile 83 product Description 83 mechanism Of Action 83 r&d Progress 83 gcs-100 - Drug Profile 85 product Description 85 mechanism Of Action 85 r&d Progress 85 cenicriviroc - Drug Profile 87 product Description 87 mechanism Of Action 87 r&d Progress 87 pn-2xxx - Drug Profile 89 product Description 89 mechanism Of Action 89 r&d Progress 89 jkb-121 - Drug Profile 90 product Description 90 mechanism Of Action 90 r&d Progress 90 jkb-119 - Drug Profile 91 product Description 91 mechanism Of Action 91 r&d Progress 91 ak-20 - Drug Profile 92 product Description 92 mechanism Of Action 92 r&d Progress 92 pbi-4050 - Drug Profile 93 product Description 93 mechanism Of Action 93 r&d Progress 93 cnxfc-010 - Drug Profile 94 product Description 94 mechanism Of Action 94 r&d Progress 94 isis-dgat2rx - Drug Profile 95 product Description 95 mechanism Of Action 95 r&d Progress 95 zgn-839 - Drug Profile 96 product Description 96 mechanism Of Action 96 r&d Progress 96 remogliflozin Etabonate - Drug Profile 97 product Description 97 mechanism Of Action 97 r&d Progress 97 small Molecule To Inhibit Scd-1 For Nash - Drug Profile 99 product Description 99 mechanism Of Action 99 r&d Progress 99 px-103 - Drug Profile 100 product Description 100 mechanism Of Action 100 r&d Progress 100 stnm-09 - Drug Profile 101 product Description 101 mechanism Of Action 101 r&d Progress 101 Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014
  4. 4. small Moleucles To Activate Ampk For Fatty Liver Disease - Drug Profile 102 product Description 102 mechanism Of Action 102 r&d Progress 102 non-alcoholic Steatohepatitis Recent Pipeline Updates 103 non-alcoholic Steatohepatitis Dormant Projects 133 non-alcoholic Steatohepatitis Discontinued Products 134 non-alcoholic Steatohepatitis Product Development Milestones 135 featured News & Press Releases 135 jan 14, 2014: Medicinova Announces Positive Results In Nash Mouse Model With Mn-001 And Prepares To Initiate Phase 2 Trial In The U.s. 135 jan 12, 2014: Intercept Reports Additional Details About Flint Trial Provided By Niddk 135 jan 09, 2014: Intercept Announces Nash Primary Endpoint Met: Flint Trial Stopped Early For Efficacy Based On Highly Statistically Significant Improvement In Liver Histology 136 nov 12, 2013: Galectin Therapeutics Reports Update On Enrollment Of First Cohort Of Phase 1 Clinical Trial 137 sep 10, 2013: Galectin Therapeutics Receives Us Patent For Potential Ground-breaking Treatment For Fatty Liver Disease 138 jul 01, 2013: Galectin Therapeutics Submits Fast Track Application To Fda For Gr-md-02 In Treatment Of Fatty Liver Disease With Advanced Fibrosis 139 jun 26, 2013: Medicinova To Initiate Preclinical Trial Of Mn-001 In Non-alcoholic Steatohepatitis 139 jun 06, 2013: Cti Announces Collaboration Agreement With Galectin Therapeutics On New Phase I Clinical Trial Of Gr-md-02 For Treatment Of Non-alcoholic Steatohepatitis 139 may 27, 2013: Genfit Announces Publication Of Data On Efficacy And Mechanism Of Action Of Gft505 In Journal Hepatology 140 apr 30, 2013: Genfit Presents Data On Gft505 At International Liver Congress Of Easl 2013 140 appendix 142 methodology 142 coverage 142 secondary Research 142 primary Research 142 expert Panel Validation 142 contact Us 143 disclaimer 143 ResearchMoz( is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: Website: Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014